Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 27,000 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Alessandra Cesano sold 27,000 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $3.37, for a total value of $90,990.00. Following the completion of the transaction, the director owned 41,850 shares of the company's stock, valued at $141,034.50. This trade represents a 39.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Alessandra Cesano also recently made the following trade(s):

• On Friday, June 13th, Alessandra Cesano sold 12,150 shares of Puma Biotechnology stock. The stock was sold at an average price of $3.40, for a total value of $41,310.00.

Puma Biotechnology Stock Down 1.4%

Shares of PBYI traded down $0.05 during midday trading on Thursday, reaching $3.40. 158,704 shares of the stock were exchanged, compared to its average volume of 418,940. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $4.13. The firm has a 50 day simple moving average of $3.44 and a 200-day simple moving average of $3.20. The company has a quick ratio of 1.43, a current ratio of 1.53 and a debt-to-equity ratio of 0.11. The company has a market cap of $168.74 million, a price-to-earnings ratio of 4.42 and a beta of 1.29.

Institutional Investors Weigh In On Puma Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its stake in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 6,351 shares in the last quarter. Graham Capital Management L.P. purchased a new stake in shares of Puma Biotechnology during the 4th quarter worth about $33,000. ProShare Advisors LLC bought a new position in shares of Puma Biotechnology in the 4th quarter valued at approximately $36,000. C2C Wealth Management LLC bought a new position in shares of Puma Biotechnology in the 4th quarter valued at approximately $37,000. Finally, Causeway Capital Management LLC bought a new position in shares of Puma Biotechnology in the 1st quarter valued at approximately $42,000. 61.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.